VBI Vaccines (VBIV)

Executive Summary

VBI Vaccines is a biopharmaceutical company developing immunotherapeutic vaccines for infectious diseases and cancer using its proprietary enveloped virus-like particle (eVLP) platform. The company's lead commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in several countries, including Israel and Hong Kong, and is undergoing FDA review for U.S. approval. The pipeline includes VBI-1901, a cancer vaccine targeting glioblastoma multiforme (GBM) currently in Phase 2 development, and VBI-2901, a COVID-19 vaccine candidate leveraging the eVLP technology. With a strong platform and a clear focus on unmet medical needs, VBI is positioned to address large markets in both infectious disease and oncology. The company's near-term value hinges on regulatory milestones for Sci-B-Vac in the U.S. and clinical data readouts for VBI-1901.

Upcoming Catalysts (preview)

• Q3 2026FDA decision on Sci-B-Vac (HBV vaccine) Biologics License Application (BLA)70% success
• Q4 2026Phase 2 data readout for VBI-1901 (GBM cancer vaccine)50% success
• TBDPotential partnership or licensing deal for VBI-2901 (COVID-19 vaccine) or other pipeline assets40% success